NASDAQ:ACRXAcelRx Pharmaceuticals Stock Price, Forecast & News

AcelRx Pharmaceuticals' stock was trading at $1.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ACRX shares have increased by 24.6% and is now trading at $1.52. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) issued its quarterly earnings results on Monday, May, 11th. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.03. The specialty pharmaceutical company had revenue of $0.39 million for the quarter, compared to analysts' expectations of $2.65 million. View AcelRx Pharmaceuticals' earnings history.

3 analysts have issued 1 year price targets for AcelRx Pharmaceuticals' shares. Their forecasts range from $2.00 to $8.00. On average, they expect AcelRx Pharmaceuticals' share price to reach $5.67 in the next twelve months. This suggests a possible upside of 272.8% from the stock's current price. View analysts' price targets for AcelRx Pharmaceuticals.

News coverage about ACRX stock has trended somewhat negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AcelRx Pharmaceuticals earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutAcelRx Pharmaceuticals.

Some companies that are related to AcelRx Pharmaceuticals include DURECT (DRRX), Beyondspring (BYSI), Emisphere Technologies (EMIS), Prothena (PRTA), Dynavax Technologies (DVAX), Passage Bio (IMRA), Puma Biotechnology (PBYI), Catalyst Pharmaceuticals (CPRX), Satsuma Pharmaceuticals (STSA), Calithera Biosciences (CALA), Merus (MRUS), RAPT Therapeutics (RAPT), Mirum Pharmaceuticals (MIRM), Protagonist Therapeutics (PTGX) and Fulcrum Therapeutics (FULC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Amarin (AMRN), Amicus Therapeutics (FOLD), Novavax (NVAX), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX), Cyberark Software (CYBR), Fitbit (FIT) and Flexion Therapeutics (FLXN).

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

AcelRx Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.04%), State Street Corp (1.77%), Geode Capital Management LLC (1.43%), Morgan Stanley (0.37%), Bank of New York Mellon Corp (0.29%) and Wells Fargo & Company MN (0.27%). Company insiders that own AcelRx Pharmaceuticals stock include Badri N Dasu, Lawrence G Hamel, Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View institutional ownership trends for AcelRx Pharmaceuticals.

ACRX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Group AG, Lincoln Capital Corp, and Bank of New York Mellon Corp. View insider buying and selling activity for AcelRx Pharmaceuticals.

ACRX stock was purchased by a variety of institutional investors in the last quarter, including Robertson Stephens Wealth Management LLC, Geode Capital Management LLC, BlackRock Inc., Wells Fargo & Company MN, State Street Corp, SG Americas Securities LLC, Meeder Asset Management Inc., and Alliancebernstein L.P.. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Mark G Edwards, Pamela P Palmer, Raffi Asadorian, and Vincent J Angotti. View insider buying and selling activity for AcelRx Pharmaceuticals.

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ACRX stock can currently be purchased for approximately $1.52.

AcelRx Pharmaceuticals has a market capitalization of $122.76 million and generates $2.29 million in revenue each year. The specialty pharmaceutical company earns $-53,240,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. AcelRx Pharmaceuticals employs 61 workers across the globe.

The official website for AcelRx Pharmaceuticals is www.acelrx.com.

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]